Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: A hypothesis

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 9, 2008, Pages 3295-3298

  Horwitz, Kathryn B ^a,b   Sartorius, Carol A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CONJUGATED ESTROGEN; CYTOKERATIN 18; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HERMES ANTIGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER STEM CELL; CARCINOGENESIS; CELL ACTIVATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; GENE EXPRESSION PROFILING; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; MAMMOGRAPHY; MITOGENESIS; MITOGENICITY; MONOTHERAPY; NOTE; PRIORITY JOURNAL; TUMOR CELL; WOMEN'S HEALTH;

EID: 51649125766     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0938     Document Type: Note

References (19)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D 2000 Molecular portraits of human breast tumours. Nature 406:747-752
2. Reya T, Morrison SJ, Clarke MF, Weissman IL 2001 Stem cells, cancer, and cancer stem cells. Nature 414:105-111
3. Clarke RB 2006 Ovarian steroids and the human breast: regulation of stem cells and cell proliferation. Maturitas 54:327-334
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF 2003 Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
5. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS 2005 A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 277:443-456
6. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS 2003 Stem cells in normal breast development and breast cancer. Cell Prolif 36(Suppl 1):59-72
7. Dontu G, El-Ashry D, Wicha MS 2004 Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193-197
8. Sartorius CA, Harvell DM, Shen T, Horwitz KB 2005 Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 65:9779-9788
9. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA 2008 Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 105:5774-5779
10. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
11. Beral V, Million Women Study Collaborators 2003 Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362:419-427
12. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F 2005 Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448-454
13. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL 2008 Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167:1207-1216
14. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagado R, Holmqvist M, Maenpa J; on behalf of the HABITS Study Group 2008 Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Institute 100:475-482
15. Santen RJ 2003 Risk of breast cancer with progestins: critical assessment of current data. Steroids 68:953-964
16. Welch HG, Black WC 1997 Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Int Med 127:1023-1028
17. Pollei SR, Mettler Jr FA, Bartow SA, Moradian G, Moskowitz M 1987 Occult breast cancer: prevalence and radiographic detectability. Radiology 163:459-462
18. Ross JS, Symmans, WF, Pusztai L, Hortobagyi G 2007 Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Can Res 13:2831-2835
19. Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M 2005 Use of the Levonorgestrel-releasing intrauterine system and breast cancer. Obst Gynecol 106:813-817